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Abstract
AIM
To investigate the outcomes and recurrences of pT1b 
esophageal adenocarcinoma (EAC) following endoscopic 
mucosal resection (EMR) and associated treatments.  
METHODS
Patients undergoing EMR with pathologically confirmed 
T1b EAC at two academic referral centers were 
retrospectively identified. Patients were divided into 4 
groups based on treatment following EMR: Endoscopic 
therapy alone (group A), endoscopic therapy with either 
chemotherapy, radiation or both (group B), surgical 
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Retrospective Study
resection (group C) or no further treatment/lost to 
follow-up (< 12 mo) (group D). Pathology specimens 
were reviewed by a central pathologist. Follow-up 
data was obtained from the academic centers, primary 
care physicians and/or referring physicians. Univariate 
analysis was performed to identify factors predicting 
recurrence of EAC. 
RESULTS 
Fifty-three patients with T1b EAC underwent EMR, of 
which 32 (60%) had adequate follow-up ≥ 12 mo 
(median 34 mo, range 12-103). There were 16 patients 
in group A, 9 in group B, 7 in group C and 21 in group 
D. Median follow-up in groups A to C was 34 mo (range 
12-103). Recurrent EAC developed overall in 9 patients 
(28%) including 6 (38%) in group A (median: 21 mo, 
range: 6-73), 1 (11%) in group B (median: 30 mo, 
range: 30-30) and 2 (29%) in group C (median 21 mo, 
range: 7-35. Six of 9 recurrences were local; of the 6 
recurrences, 5 were treated with endoscopy alone. No 
predictors of recurrence of EAC were identified. 
CONCLUSION 
Endoscopic therapy of T1b EAC may be a reasonable 
strategy for a subset of patients including those either 
refusing or medically unfit for esophagectomy. 
Key words: Esophageal cancer; Submucosal; T1b; 
Endoscopic mucosal resection; Chemotherapy; Esophagec-
tomy 
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Core tip: Endoscopic eradication therapy (EET) is 
reported as safe and effective for low risk T1b esophageal 
adenocarcinomas (EAC), but overall data is lacking. We 
retrospectively evaluated patients with T1b EAC treated 
with EET, EET with chemotherapy and/or radiation therapy 
and surgical resection. The overall recurrence rate was 
28% at median 21 mo (range: 6-73) following EMR. In 
those treated with endoscopic mucosal resection alone, 
recurrence rate was 38% at median 21 mo (range: 6-73). 
Six of the 9 recurrences were local; 5 were treated with 
endoscopy alone. EET of T1b EAC may be a reasonable 
treatment strategy for a subset of these patients. 
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INTRODUCTION
Due to the inherent morbidity and rare mortality 
associated with esophagectomy and lymph node 
dissection, endoscopic eradication therapy [including 
endoscopic mucosal resection (EMR) and ablative 
techniques] has been increasingly used as a safe, 
effective and potentially curative organ-sparing 
procedure to treat high grade dysplasia (Tis lesions) 
and intramucosal esophageal cancer (T1a lesions)[1-5]. 
When complete resection or eradication of T1a cancers 
is confirmed, disease is generally considered cured due 
to the low rate of reported lymph node metastasis (< 
2%) in these patients[6]. Tumors that penetrate the 
submucosa of the esophagus (T1b cancers), however 
metastasize to regional lymph nodes in up to 30% 
of cases and the likelihood for metastases increases 
the further the tumor penetrates from the first third 
(sm1) into the lower two thirds (sm2 and sm3) of the 
submucosal layer[7-11]. Therefore, endoscopic eradication 
therapies (EET) have generally not been employed in 
patients with T1b cancers.  
The use of EET for primary treatment of T1b 
tumors was initially reported in patients with “low risk” 
submucosal esophageal cancers (macroscopically 
polypoid or flat, invasion limited to the upper 1/3 of 
the submucosa, no invasion of the vessels or lymphatic 
system, well to moderate tumor differentiation); this 
has more recently been updated in a larger series (n 
= 66) from the same group with similar characteristics 
showing recurrent or metachronous carcinomas 
developed in 19% of patients with an estimated 5 year 
survival rate of 84%[12,13]. A study from two referral 
centers in the Netherlands examined EET of deep T1a 
and T1b EAC (n = 75) with an overall recurrence rate 
of 9%[14]. A study from a tertiary center in the United 
States reported a group of patients (n = 29) with T1b 
EAC with sm1 (46%) and sm2-3 (54%) invasion that 
underwent either EET, chemo/radiation or a combination 
of both and showed mean survival of 34.8 mo with a 
38% mortality rate[15]. 
To our knowledge, there are no studies examining 
the outcomes and predictors of disease recurrence in 
patients with pathologically staged T1b esophageal 
cancer treated with EET alone, surgery, or adjuvant 
therapy following endoscopic resection. Identification 
of predictive factors for recurrence and outcomes 
following endoscopic therapy in this population would 
help to identify and tailor appropriate treatment. For 
this reason, we aimed to (1) retrospectively evaluate 
the clinical outcomes of pT1b esophageal cancers 
following EMR; (2) to compare the recurrence rates of 
cancer when patients are treated with EET alone, EET 
in association with chemotherapy, radiation therapy 
or both and surgical resection; and (3) to evaluate 
the predictors of recurrence of T1b esophageal cancer 
following EMR.
MATERIALS AND METHODS
Study population and design
All patients age ≥ 18 years of age who underwent 
EMR of the esophagus from 2001 to 2013 at India-
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na University Medical Center and the University of 
Michigan were retrospectively identified from institu-
tional endoscopic databases. Patient charts were 
then reviewed to identify the subset of patients with 
pathologically (p) staged T1b esophageal cancer that 
comprised the study population. Patients with treatment 
by endoscopic submucosal dissection or ≤ 12 mo of 
follow-up after resection were excluded. Approval for 
this study was obtained by the institutional review 
boards at both participating institutions prior to any 
study activities. 
Pre-procedure imaging with CT and/or PET scans 
was initially obtained in all patients to exclude distant 
metastasis. Endoscopic ultrasound (EUS) was also used 
in selected patients to assess the depth of any visualized 
mass or detect and sample any suspicious lymph nodes. 
Prior to EMR, all patients underwent EGD with a detailed 
exam of the mucosa of the esophagus and gastric 
cardia. The use of advanced imaging techniques such 
as narrow band imaging and chromoendoscopy was at 
the discretion of the endoscopist. After identification of 
the site(s) for resection, either cap-assisted (Olympus 
America Inc., Center Valley, PA) or band ligation-
assisted EMR (Cook Medical Inc., Winston Salem, NC) 
was performed. The specimens retrieved were placed 
into formalin and sent to pathology for evaluation 
for examination by an experienced gastrointestinal 
pathologist.  
Treatment groups
Treatment after identification of a pT1b esophageal 
cancer at each institution was at the discretion of the 
endoscopist as well as referring physicians based on the 
pathology findings, patient comorbidities and patient 
wishes. For study purposes, treatment after EMR 
was classified as utilizing endoscopy alone (group A), 
endoscopy with either chemotherapy, radiation or both 
(group B), surgical resection alone (group C), or no 
further treatment or lost to follow-up (group D). Patients 
in group A underwent additional EMR with or without 
ablation, surveillance endoscopies and cross-sectional 
imaging as determined by the treating physicians. 
Pathology assessment
Endoscopic resection specimens from both institutions 
were initially reviewed by local pathologists. For the 
current study, slides from both institutions were re-
reviewed by a single gastrointestinal pathologist at 
Indiana University for the following characteristics: Depth 
of tumor invasion (sm1 vs sm2/3), tumor differentiation 
(well, moderate and poor), presence or absence of 
lymphatic or perineural invasion (LPI) and the status 
of deep and lateral margins following resection. A T1b 
esophageal cancer was defined as tumor extending 
beyond the muscularis mucosa and into tissue which 
contains submucosal glands or tumor adjacent to 
large caliber arteries which would not be present in the 
mucosa. Tumors classified as sm1 had invasion of tumor 
into the upper 1/3 of the submucosa and sm2/3 depth 
of invasion was defined as invasion into the lower 2/3 of 
the submucosa. Tumor differentiation was determined 
based on standard histologic features such as growth 
pattern, gland formation and degree of atypia. LPI was 
defined as the presence of malignant tumor cells within 
a lymphatic channel or neural bundle. 
Follow-up
Follow-up cross-sectional imaging and endoscopy were 
performed at the discretion of the endoscopist and 
consulting physicians at each institution. These data 
on the study population were obtained both from the 
treating institution as well as referring physicians and 
primary care physicians and consisted of endoscopic 
procedures, imaging studies and clinic visits. The end 
point of follow-up for study patients included: Death, 
surgery for esophageal cancer, or loss of patient contact. 
Patient death was identified by reviewing medical 
records or by searching the Social Security Death 
Index. Tumor recurrence was diagnosed when biopsies 
from the previous or adjacent esophageal EMR site or 
from either regional or metastatic sites demonstrated 
pathology consistent with the primary cancer. A univariate 
analysis was performed in order to identify factors 
predicting recurrence of cancer after EMR and associated 
treatment. Variables analyzed in the analysis included: 
method of EMR (cap vs band), pathology depth (sm1 vs 
sm2/3), initial tumor location (proximal 2/3 vs distal 1/3 
of the esophagus), lymphovascular and/or perineural 
invasion, degree of tumor differentiation, positive vs 
negative deep and lateral EMR margins, and primary 
treatment modality (endoscopic ± chemotherapy and/or 
radiation therapy vs surgery). 
Statistical analysis 
The data were analyzed descriptively using means, 
medians, ranges and standard deviations. The variables 
between groups were compared using Fisher’s exact 
tests (GraphPad). P < 0.05 was considered statistically 
significant. 
RESULTS
Sixty patients who underwent EMR were found to 
have pT1b esophageal cancer, including 53 (88%) 
with adenocarcinoma and 7 (12%) with squamous cell 
carcinoma. Of the 53 patients with adenocarcinomas, 
32 patients (60%) had adequate follow-up after EMR of 
≥ 12 mo (median 34 mo, range 12-103). There were 
16 patients in group A, 9 patients in group B, 7 patients 
in group C and 21 patients in group D (8 with no further 
treatment and 13 without required 12 mo follow-up). 
Demographics, EMR method (cap vs band), pathology 
findings and follow-up are summarized in Table 1. 
Pathology in patients who underwent esophagectomy 
(group C) showed no residual dysplasia or malignancy 
in 2, adenocarcinoma with negative nodes in 1, 
dysplasia in 3 and 1 with unknown findings. 
No recurrence of carcinoma developed in 23 patients 
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(72%) during a median follow-up of 31 mo (range 
12-103). Recurrent adenocarcinoma developed in 9 
(28%) patients among all 3 groups. There was no 
statistically significant differences between recurrences 
in group A (n = 6; 38%), group B (n = 1; 11%) and 
group C (n = 2; 29%). Median time to recurrence was 
21 mo (range 6-73) in group A, 30 mo in group B, 
and 9 mo (range 8-10) in group C. Of the recurrences 
in group A, 5 were local and 1 was metastatic. These 
local recurrences in group A were treated with further 
EET alone in two, EET and radiation in one, EET with 
chemotherapy with radiation in one and radiation in 
one. The single metastatic recurrence in group A was 
treated with chemotherapy and radiation. The single 
recurrence in group B was metastatic and had no 
further treatment. The two recurrences in group C were 
766 December 16, 2016|Volume 8|Issue 20|WJGE|www.wjgnet.com
Group A (n  = 16) Group B (n  = 9) Group C (n  = 7) Group D (n  = 21) Overall (n  = 53)
  Average age, yr 75 ± 78 70 ± 14 62 ± 5 72 ± 13 71 ± 12
  Median follow-up after EMR, mo 
  (range)
       34 (12-102)      27 (12-56)      49 (13-103) N/A 34 (12-103) 
(for groups A-C, n = 32)
  EMR method, n (%)
     Cap   6 (38) 0 (0) 2 (29)   4 (19) 12 (23)
     Band 10 (62)     9 (100) 5 (71) 17 (81) 41 (77)
  Pathology depth, n (%)
     sm1   6 (38)   4 (44) 1 (14)   2 (10) 13 (25)
     sm2/3 10 (62)   5 (56) 6 (86) 19 (90) 40 (75)
  Tumor location, n (%)
     Proximal two-thirds   2 (13)   1 (11) 1 (14)   5 (24)   9 (17)
     Distal one-third 14 (88)   8 (89) 6 (86) 16 (76) 44 (83)
  LPI, n (%)
     Yes 1 (6)   1 (11)             0 (0)   3 (14) 5 (9)
     No 15 (94)   8 (89)   7 (100) 18 (86) 48 (91)
  Differentiation, n (%)
     Well-moderate 14 (88)   6 (67)   7 (100) 15 (71) 42 (79)
     Poor   2 (13)   3 (33)             0 (0)   6 (29) 11 (21)
  EMR margins for cancer, n (%)
     Deep -/lateral -   6 (38)   2 (22) 1 (14)   2 (10) 11 (21)
     Deep -/lateral +   5 (31)   1 (11) 1 (14)   4 (19) 11 (21)
     Deep +/lateral +   4 (25)   6 (66) 5 (71) 13 (62) 28 (53)
     Deep +/lateral - 1 (6) 0 (0)             0 (0)   2 (10) 3 (6)
  Recurrences, n (%)
     Yes   6 (38)   1 (11) 2 (29) N/A   9 (28)
     No 10 (63)   8 (88) 5 (71) 23 (72)
     Median time to recurrence 
     (mo, range)
   21 (6-73)      30 (30-30)   21 (7-35) 21 (6-73)
(for groups A-C, n = 32)
  Location of recurrence
     Local                 5               0             1 N/A 6
     Metastatic                 1               1             1 3
Table 1  Characteristics of T1b esophageal adenocarcinoma by treatment modality following endoscopic mucosal resection 
EMR: Endoscopic mucosal resection; LPI: Lymphatic/perineural invasion.
  Variable Recurrence rates P  value
  EMR method  
     Cap 4/8 (50) 0.18
     Band   5/24 (21)
  Pathology depth
     sm1   3/11 (27) 0.11
     sm2/3   6/21 (29)
  Tumor location 
     Proximal 2/3 esophagus 2/4 (50) 0.56
     Distal 1/3 esophagus   7/28 (25)
  LPI
     Yes                 0/2 (0) 1.00
     No   9/30 (30)
  Differentiation
     Well-moderate  8/27 (30) 1.00
     Poor 1/5 (20)
  Deep EMR margins 
     Positive   4/16 (25) 1.00
     Negative  5/16 (31)
  Lateral EMR margins 
     Positive   6/22 (27) 1.00
     Negative   3/10 (30)
  Primary treatment 
     Endoscopic +/- CRT   7/25 (28) 1.00
     Surgical 2/7 (29)
Table 2  Recurrence rates of esophageal adenocarcinoma by 
investigated risk factors of esophageal adenocarcinoma (n  = 32) 
n  (%)
EMR: Endoscopic mucosal resection; LPI: Lymphatic/perineural invasion; 
CRT: Chemoradiation.
  EUS staging (n  = 51) Pathologic staging
pT1sm1 
(n  = 12)
pT1sm2/3 
(n  = 39)
Overall (all pT1b) 
(n  = 51)
  uT0 Nx   0   1   1
  uT1 Nx 11 36 47
  uT2 Nx   1   2   3
  T staging accuracy 91.7% 92.3% 92.2%
Table 3  Endoscopic ultrasound staging/path accuracy for 
T1b esophageal adenocarcinoma 
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low risk T1bsm1 EAC) and our study which evaluated 
outcomes for all T1b patients. The rate of recurrence 
in our study does compare favorably to that previously 
reported for a small cohort of patients with sm2/3 
invasion of 33%[14]. 
We found that most recurrences following EMR in 
those treated at least partly endoscopically (groups A 
and B) were localized. Of the patients who underwent 
EET alone, there were 6 recurrences (38%), five of 
which were localized to the esophagus with only 1 
having metastatic disease 21 mo following EMR. Of 
the patients who underwent EET + chemotherapy 
and/or radiation, 1 (11%) had metastatic recurrence 
30 mo after resection. Therefore, EET with or without 
chemotherapy or radiation, may be a reasonable initial 
treatment strategy for a subset of patients with T1b 
EAC, especially those that refuse or are unfit for surgical 
intervention due to medical comorbidities or home 
support since most recurrences appear to be localized.
In those that underwent esophagectomy, we identi-
fied 2 recurrences out of 7 patients (29%). Our recur­
rence rate is similar to a recent retrospective study 
including 26 patients with T1b EAC undergoing surgical 
resection which showed a 23% recurrence rate[17]. 
Recurrence or metastatic disease discovered after 
resection may be related to micrometastatic disease 
that was unable to be identified prior to esophagectomy.
Overall, we found a 3-year survival rate of 78% 
when evaluating the patients in our study; more 
specifically a rate of 87% in those treated with EET only 
and 56% in those treated with EET + chemotherapy 
and/or radiation. When combining those treated at 
least partly endoscopically, the survival rate at 3 years 
was 76%. Manner et al[13] previously have shown an 
estimated 5-year survival rate of 84% in those treated 
with EET with “low risk” T1b. Our lower survival rate 
is likely reflected in our patient population, as we 
evaluated all patients with T1b EAC and not only those 
with “low risk” disease. Tian et al[15] reported on a group 
of patients (n = 29) more similar to our cohort including 
“low risk” and higher risk T1b EAC patients [sm1 (46%) 
and sm2-3 (54%) invasion] that underwent either EET, 
chemo/radiation or a combination of both and showed a 
local in one and metastatic in one. The local recurrence 
in group C was treated with chemotherapy and the 
metastatic recurrence in group C was treated with 
local resection of a hepatic metastasis. No predictors 
of recurrence of adenocarcinoma were identified on 
univariate analysis (Table 2).
Of the 32 patients in groups A, B and C, 7 died 
within 3 years of EMR giving an overall 3 year mortality 
for all causes of 22%. Specifically within each group, 3 
year mortality rates were 13% in group A (2/16), 44% 
in group B (4/9), and 14% in group C (1/7). 
EUS was performed prior to EMR in 51 (96%) of 
the 53 patients with T1b EAC. T staging accuracy (for 
T1 malignancy) on EUS for pT1b tumors overall was 
92%; specifically for pT1sm1 tumors was 92% and for 
pT1sm2/3 tumors was 92% (Table 3).
DISCUSSION
Endoscopic therapy is an alternative to esophagectomy 
for mucosal EAC in select populations[1] and has been 
included in national guidelines as a curative form of 
treatment[16]. More recently, “low risk” T1b EAC have 
been treated with EET as primary therapy in Germany 
with recurrence rates ranging from 19% to 28% and 
estimated five­year survival rates up to 84%[12,13]. Two 
small studies from the United States (n = 15) and the 
Netherlands (n = 18) showed a recurrence rate of 21% 
and 17% respectively, with all recurrences in the latter 
study having initial sm2/3 depth of invasion[14,15]. 
In our study, we aimed to retrospectively evaluate 
and compare outcomes of various treatments for T1b 
EAC after EMR and to evaluate predictors of recur-
rence after those treatments. We found an overall 
recurrence rate of 28%, which was not statistically 
different between those treated with endotherapy alone 
(38%), chemotherapy, radiation or both (11%) or 
those undergoing esophagectomy (29%). The overall 
observed rate of recurrence in our study for those 
undergoing EET alone is higher than previously reported 
in patients undergoing EET as primary therapy (Table 4). 
These differences likely reflect differences in population 
between most other series (which included primarily 
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  Ref. # Patients Depth of 
invasion
Histology Margins Remission Recurrence Survival
  Manner et al[12] 21 sm1 Well to moderately differentiated, 
no lymphovascular invasion
Lateral margins 
negative in 12
95% at mean 5.3 
mo
28% at mean 
62 mo (range 
45-89)
67% estimated 5-yr 
survival
  Alvarez Herrero et al[14] 18 sm1 and 
sm2/3
Well, moderately and poorly 
differentiated, some with 
lymphovascular invasion
Not reported Not reported 17% Not reported
  Tian et al[15] 29 sm1 and
sm2-3
Not reported Not reported Not reported Not reported 62% with median 
duration 34.8 mo
  Manner et al[13] 66 sm1 Well to moderately differentiated, 
no lymphovascular invasion
Not reported 84% at mean 4.5 
mo
21% at mean 22 
mo (range 6-60)
84% estimated 5-yr 
survival
Table 4  Studies evaluating endoscopic management of T1b esophageal adenocarcinoma
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cancers or the use of EET in conjunction with other treatment modalities such as 
chemotherapy or radiation.
Innovations and breakthroughs
In the current study, the authors attempted to evaluate the clinical outcomes and 
recurrence rates of T1b esophageal cancers treated with EET alone, as well as 
those treated with EET in conjunction with chemotherapy and/or radiation as 
well as those undergoing surgical resection. In addition, the authors attempted to 
identify factors that may predict recurrence.
Applications
For patients with T1b esophageal cancer and treated with EET alone, the 
recurrence rate was 38%; therefore treatment with adjuvant therapy in 
conjunction with EET seems reasonable in patients that are either unable to or 
refuse to undergo esophagectomy. No particular variables were identified that 
predict recurrence of cancer in this population following EMR. Further research 
in these areas regarding management and risk stratification will be required.
Terminology
T1b esophageal adenocarcinoma - cancer which invades into but not through 
the submucosal layer; Endoscopic eradication therapy - Endoscopic treatment 
including endoscopic mucosal resection and ablative techniques such as 
radiofrequency ablation and cryotherapy.
Peer-review
A retrospective study is reported to investigate outcomes and recurrences of T1b 
esophageal adenocarcinomas following EMR. The topic is relevant, and the data 
collection done by the authors are very useful. 
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with older age and lymphovascular invasion, although 
it did not specifically assess for predictors of cancer 
recurrence[18]. In our study, we were unable to identify 
lymphatic and perineural invasion as predictors of 
recurrence. 
A recent prospective study from Germany evaluated 
the risk of lymph node metastases when comparing 
“low risk” (sm1 invasion) to “high risk” (sm2/3 invasion) 
T1b EAC in patients treated both surgically and with 
EET, and found a 2% risk of lymph node metastasis 
in pT1bsm1 tumors and 9% in pT1bsm2/3 tumors, 
which is lower than has generally been reported in prior 
studies[19]. In our study which includes both sm1 and 
sm2/3 invasion, we similarly found 6% of patients with 
metastatic lymph nodes either on initial staging or on 
surveillance (one each with sm1 and sm2/3 tumors). 
Previous studies have shown excellent accuracy 
for staging both T1a and T1b esophageal cancers. 
Specifically, a previous meta-analysis showed good 
accuracy with area under the curve > 0.93 for both T1a 
and T1b esophageal cancers[20]. We also demonstrated 
overall diagnostic accuracy of 91% for pT1 lesions in our 
cohort. 
Our study has several strengths including data from 
all T1b cancers removed by EMR from two tertiary care 
referral centers, re-review of all pathology by a single 
pathologist, and evaluation of outcomes of medical and 
surgical therapy for these patients. However, our study 
is limited by the number of patients who refused further 
therapy or were lost to follow-up which may limit the 
ability to compare outcomes from various treatments 
after resection.  
In conclusion, our study shows that endoscopic 
therapy alone following EMR of a T1b cancer is 
associated with a recurrence rate of 38%. Therefore, 
treatment with adjuvant therapy appears reasonable 
in this population when possible. No particular variable 
is predictive of recurrence following EMR of T1b 
adenocarcinomas. Therefore, future research into the 
management and risk stratification of these patients 
after EMR is warranted.  
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